Arbios to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
October 31 2007 - 4:30PM
PR Newswire (US)
WALTHAM, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Arbios Systems,
Inc. (OTC:ABOS) (BULLETIN BOARD: ABOS) today announced that it will
present at the Acumen Biofin Rodman & Renshaw 9th Annual
Healthcare Conference to be held November 5-7, 2007, at the New
York Palace Hotel in New York City. Shawn Cain, Interim President
and CEO, Arbios Systems, Inc., will present on Wednesday, November
7th, 2007, at 2:20 p.m. Eastern Time. He will provide a company
overview including recent clinical information on the Company's
SEPET (TM) Liver Assist Device and the recently announced
manufacturing agreements with NxStage Medical, Inc. and Membrana
Gmbh. The presentation will be available at:
http://www.wsw.com/webcast/rrshq12/abos as a live, audio webcast,
then archived afterwards for 90 days. About Arbios' SEPET(TM) Liver
Assist Device The SEPET(TM) Liver Assist Device is a sterile,
disposable cartridge containing microporous hollow fibers with
proprietary permeability characteristics. When a patient's blood is
passed through these fibers, blood plasma components of specific
molecular weights are expressed through the micropores, thereby
cleansing the blood of harmful impurities (e.g., hepatic failure
toxins as well as various mediators of inflammation and inhibitors
of liver regeneration). These substances would otherwise
progressively accumulate in the patient's bloodstream during liver
failure, causing hypotension, increasing risk of sepsis development
and accelerating damage to the liver, lungs and other organs,
including the brain and kidneys, and suppressing the function and
regeneration of the liver. SEPET(TM) is designed for use with
standard blood dialysis systems available in hospital intensive
care units. According to the American Liver Foundation, chronic
liver disease is the tenth leading cause of death in the United
States, resulting in approximately $10 billion in annual healthcare
costs. There is currently no satisfactory therapy available to
treat patients in liver failure, other than maintenance and
monitoring of vital functions and keeping patients stable through
provision of intravenous fluids and blood products, administration
of antibiotics and support of vital functions, such as respiration.
About Arbios Systems Arbios Systems, Inc. is developing proprietary
medical devices and cell- based therapies to enhance the survival
of millions of patients each year who experience, or are at risk
for, life-threatening episodes of liver failure. The Arbios product
candidate portfolio includes the SEPET(TM) Liver Assist Device, a
novel blood purification therapy that provides enhanced "liver
dialysis," and the HepatAssist(TM) Cell-Based Liver Support System,
a bio- artificial liver that combines blood detoxification with
liver cell therapy to replace whole liver function in patients with
the most severe forms of liver failure. For more information on the
Company, please visit http://www.arbios.com/. This press release
contains forward-looking statements that involve risks and
uncertainties that could cause actual events or results to differ
materially from the events or results described in the
forward-looking statements, including risks or uncertainties
related to future markets for the Company's products and goals and
objectives of the Company's product and clinical development
programs. These statements represent the judgment of Arbios'
management as of this date and are subject to risks and
uncertainties that could materially affect the Company. Arbios
cautions investors that there can be no assurance that actual
results or business conditions will not differ materially from
those projected or suggested in such forward-looking statements.
Please refer to our Annual Report on Form 10-KSB for the fiscal
year ended December 31, 2006, and to our subsequent Quarterly
Reports on Form 10-QSB, for a description of risks that may affect
our results or business conditions. The Company does not undertake
any obligation to publicly release the result of any revisions to
such forward-looking statements that may be made to reflect events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events except as required by law. SEPET(TM) and
HepatAssist(TM) are trademarks of Arbios Systems, Inc. DATASOURCE:
Arbios Systems, Inc. CONTACT: CONTACT AT ARBIOS: Shawn Cain,
Interim President and CEO, +1-781-839-7292, or Scott Hayashi, CFO,
+1-626-356-3105, or CONTACT FOR INVESTOR RELATIONS: Lisa Wilson,
+1-212-759-3929, or Doug MacDougall +1-508-647-0209 Web site:
http://www.arbios.com/
Copyright